302 Using the 21-gene Breast Cancer Assay in Adjuvant Decision-making in ER-positive (ER+) Early Breast Cancer (EBC) is Cost-effective: Results of a Large Prospective German Multicenter Study

MLA

J-U Blohmer, et al. “302 Using the 21-Gene Breast Cancer Assay in Adjuvant Decision-Making in ER-Positive (ER+) Early Breast Cancer (EBC) Is Cost-Effective: Results of a Large Prospective German Multicenter Study.” European Journal of Cancer, vol. 48, Mar. 2012, p. S130. EBSCOhost, https://doi.org/10.1016/s0959-8049(12)70368-4.

APA

J-U Blohmer, Thorsten Kühn, Wolfgang Eiermann, K. Friedrichs, M Warm, A. Benkow, Mahdi Rezai, & Sherko Kümmel. (2012). 302 Using the 21-gene Breast Cancer Assay in Adjuvant Decision-making in ER-positive (ER+) Early Breast Cancer (EBC) is Cost-effective: Results of a Large Prospective German Multicenter Study. European Journal of Cancer, 48, S130. https://doi.org/10.1016/s0959-8049(12)70368-4

Chicago

J-U Blohmer, Thorsten Kühn, Wolfgang Eiermann, K. Friedrichs, M Warm, A. Benkow, Mahdi Rezai, and Sherko Kümmel. 2012. “302 Using the 21-Gene Breast Cancer Assay in Adjuvant Decision-Making in ER-Positive (ER+) Early Breast Cancer (EBC) Is Cost-Effective: Results of a Large Prospective German Multicenter Study.” European Journal of Cancer 48 (March): S130. doi:10.1016/s0959-8049(12)70368-4.